Synaptogenix Inc.

AI Score

0

Unlock

3.53
0.26 (7.95%)
At close: Jan 14, 2025, 2:42 PM
3.53
0.00%
After-hours Jan 14, 2025, 02:42 PM EST
undefined%
Bid 2.82
Market Cap 4.78M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 0.88
PE Ratio (ttm) 4.01
Forward PE n/a
Analyst Buy
Ask 5.12
Volume 9,460
Avg. Volume (20D) 27,603
Open 3.33
Previous Close 3.27
Day's Range 3.33 - 3.58
52-Week Range 2.32 - 7.22
Beta undefined

About SNPX

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and N...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 8, 2020
Employees 5
Stock Exchange NASDAQ
Ticker Symbol SNPX

Analyst Forecast

According to 1 analyst ratings, the average rating for SNPX stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 296.70% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
3 weeks ago · Source
+19.46%
Synaptogenix shares are trading higher after the c... Unlock content with Pro Subscription
9 months ago · Source
-2.17%
Synaptogenix shares are trading lower. The company announced a 1-for-25 reverse stock split.